|
 |
 Pre-Meeting Workshops - Annual Meeting and Exhibition 2006
Sunday, July 30
#2: Protein Expression: Things to Consider When Expressing a New Protein
Faculty Bios
Dr. E. Timothy Davies
Dr. E. Timothy Davies
graduated from the University of London with a B.Sc. (Honors)
in Microbiology in 1990. In 1995 he earned a PhD in Chemical
Engineering from the University of Manchester (UMIST). In
1996, he joined Lars Ljungdahl's laboratory at the University
of Georgia where he studied extremely oxygen-labile proteins
from anaerobes, and later worked on optimizing recombinant
protein expression in fungi and bacteria. Since 2001 Dr.
Davies has been Director of UGA's Bioexpression and Fermentation
Facility, where he has completed projects for more than 60
companies and universities. He works with a wide range of
microorganisms, optimizing upstream and downstream process
conditions, scaling processes up to the pilot plant, and
manufacturing material used in environmental and pre-clinical
pharmaceutical applications.
Dr. Dominic Esposito
Dr. Dominic Esposito received his undergraduate
degree in Chemistry from La Salle University in Philadelphia,
and his doctoral degree in Biochemistry from the Johns Hopkins
University Bloomberg School working on site-specific DNA
recombination in bacteriophage. After studying the protein-DNA
interactions of the HIV-1 integrase protein at the National
Institutes of Health in Bethesda, Maryland, Dom joined the
Protein Engineering group at Life Technologies (now Invitrogen),
where he helped to develop the Gateway recombinational cloning
technology. In 2001, Dom moved to the National Cancer Institute
in Frederick, Maryland, where he works as a Senior Scientist
and Group Leader in the SAIC-Frederick Protein Expression
Laboratory.
Dr. Lyndal Hesterberg
Dr. Lyndal Hesterberg, Ph. D. is President
and a founder of BaroFold. From 1982 - 1986, he held various
management and scientific positions at Syngene Products and
Research, a start up company focused on the development/production
of recombinant protein vaccines. In 1986, he joined Amgen,
Inc. and participated in the development of cytokine/growth
factor products. Dr. Hesterberg was a co-founder and Executive
Vice President of Scientific Affairs for BioStar, Inc., a
bio-sensor company. He served at SomaLogic, Inc, a proteomics
array company, as the Senior Director of Business Development
and Clinical Research Services. Dr. Hesterberg also provides
a range of consulting services, including immunogenicity
analysis of protein therapeutic candidates. Dr. Hesterberg
earned his Ph.D. from St. Louis University, where his thesis
research involved the structural and thermodynamic behavior
of proteins. Dr. Hesterberg completed post-doctoral training
as an EMBO Fellow at the Max Planck Institute for BioPhysical
Chemistry, Goettingen, Germany.
Dr. Robert Petrovich
Dr. Robert Petrovich received a B.S.
degree in Chemistry from Hope College followed by a Ph. D
in Biochemistry from the University of Wisconsin-Madison.
His doctoral work was done on the anaerobic-purification
and characterization of Lysine2,3-aminomutase from Clostridium
SB4 under the direction of Dr Perry Frey. He did post-doctoral
work on recombinant expression and characterization of porphobilinogen
synthase in E. coli under the direction of Dr. Eileen Jaffe
at the Fox Chase Cancer Center. In 1999 he joined the Biochemistry
group at the Novartis Agricultural Biotechnology Research
Institute. While at NABRI, he was responsible for the program
to production 100 new protein targets per year. In 2003 he
took his current position as head of the Protein Expression
Core Facility at the National Institute for Environmental
Heath Sciences.
Dr. F. William Studier
Dr. F. William Studier received a B.S.
degree from Yale University and a Ph.D. from Caltech, both
in biophysics. After postdoctoral research in Biochemistry
at the Stanford Medical School, he took a position in the
Biology Department at Brookhaven National Laboratory where
he has remained. Much of his research has been directed toward
understanding the molecular genetics of bacteriophage T7,
and the widely used T7 expression system grew out of this
work. He is currently engaged in improving techniques for
protein production for structural genomics.
His talk will cover evolution of the T7 expression system
and recent improvements in its use.
Dr. David S. Waugh
Dr. David S. Waugh graduated from Yale University in 1982 with a B.S. in Molecular
Biophysics & Biochemistry. He received his Ph.D. in Biochemistry & Molecular
Biology from Indiana University in 1989, under the direction
of Dr. Norman Pace. His doctoral dissertation, entitled "Mutational
Analysis of Catalytic Function in Ribonuclease P RNA", earned
him the Esther L. Kinlsey award for the outstanding dissertation
presented to the Graduate School at Indiana University in
1989. During 1990 and 1991 he was a postdoctoral fellow in
Dr. Robert Sauer's laboratory at the Massachusetts Institute
of Technology, where he studied structure-function relationships
in the type IIS restriction endonuclease FokI. In 1991, Dr.
Waugh joined the Biomolecular Structure Group at Hoffmann-La
Roche as head of the Macromolecular Engineering Laboratory.
He became a principal investigator at the National Cancer
Institute in 1996. Dr. Waugh currently heads the Protein
Engineering Section in the Macromolecular Crystallography
Laboratory at the NCI. His research interests revolve around
methods development for high-throughput protein expression
and purification and X-ray crystallographic studies of virulence
factors from the plague bacterium Yersinia pestis.
Back
to "Workshops" page
Protein schedule
|
|
|
|
|
